Allogene Therapeutics (ALLO) Profit After Tax (2018 - 2026)

Allogene Therapeutics has disclosed Profit After Tax across 9 years of filings, most recently posting -$42.6 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$42.6 million, up 28.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$173.8 million (up 31.14% YoY), and the FY2025 annual result was -$190.9 million, up 25.9% from the prior year.
• Profit After Tax came in at -$42.6 million for Q1 2026 at Allogene Therapeutics, down from -$38.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$38.8 million in Q4 2025 to a low of -$100.0 million in Q1 2023.
• The 5-year median for Profit After Tax is -$66.3 million (2024), against an average of -$68.2 million.
• Across the five-year window, Profit After Tax sank 113210.47% in 2022 and jumped 37.55% in 2025, its largest moves.
• Allogene Therapeutics' Profit After Tax stood at -$97.3 million in 2022, then climbed by 11.82% to -$85.8 million in 2023, then jumped by 30.12% to -$59.9 million in 2024, then jumped by 35.25% to -$38.8 million in 2025, then retreated by 9.78% to -$42.6 million in 2026.
• The last three Profit After Tax figures came in at -$42.6 million (Q1 2026), -$38.8 million (Q4 2025), and -$41.4 million (Q3 2025), per Business Quant data.